Ropeginterferon for early myelofibrosis with low-to-mid risk
Part of Blood & lymphatic clinical trials.
This Phase 2 trial studies ropeginterferon alfa-2b (a type of interferon medicine) in adults with early, lower-risk myelofibrosis. The goal is to see if it can control the disease better or improve outcomes with an acceptable safety profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or the local legal adult age) with myelofibrosis that is primary or after prior PV or ET
- Your bone marrow scarring is low (reticulin grade 0–1) and your risk is low or intermediate-1 (DIPSS)
- Your liver and kidney tests meet certain limits (bilirubin, ALT/AST, blood clotting time, and kidney filtration rate)
- You must be able to use reliable contraception during the study and for 28 days after the last dose; you must not be pregnant, and you must not breast-feed
- You cannot have used interferon (IFNα) for myelofibrosis recently (unless it was for prior PV/ET and the last dose was more than 4 weeks ago)
- You must not have certain conditions like major autoimmune disease, HIV with active issues, uncontrolled hepatitis B/C, severe eye disease, major depression/seizure history, recent other cancers, or recent alcohol/drug abuse
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This study tests a medication called ropeginterferon alfa-2b for people with certain blood cancers that have features of both myelodysplastic syndromes and myeloproliferative neoplasms. The drug may help control blood counts and reduce symptoms.
This trial tests whether adding a drug called interferon alfa-2b to the standard treatment ruxolitinib can help people with myelofibrosis. It may reduce spleen size and improve blood counts.
This study looks at how well a drug called ropeginterferon alfa-2b works for people with polycythemia vera. It aims to understand the drug's effects and safety when used as a first or later treatment option.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This Phase 1 study tests PegINFa (after a bone marrow transplant) to see if it is safe and can help control myelofibrosis. You must be eligible for transplant and meet specific donor, timing, and health criteria before starting the study drug.
Hear when a new Pre-fibrotic Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.